Medicare AdvantageCoverageMedium impact
MA08.015d, Alemtuzumab (Lemtrada®)
Independence Blue Cross·Neurology, Oncology·Pharmacy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.015d for Alemtuzumab (Lemtrada®) has been reissued with updates effective April 2, 2025. This is a pharmacy-related policy change affecting coverage or administration requirements for this multiple sclerosis medication.
Action Required
By April 2, 2025: Billing team should review the updated MA08.015d policy for Alemtuzumab (Lemtrada®) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Medicare Advantage patients receiving this medication. Update billing system and provider protocols accordingly based on the specific policy changes identified.